secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001193125-24-282407
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience sells subsidiary for $100M, licenses ADC programs, raises $100M PIPE
--------------------------------------------------------------------------------

- Sells wholly owned subsidiary Private Aadi to Kaken Investments for $100M; stockholder approval required.
- Licenses three pre-clinical ADC programs (MUC16, PTK7, SEZ6) from WuXi Biologics; upfront $44M total.
- Raises $100M via PIPE: 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.
- Appoints Baiteng Zhao, Ph.D. (ex-ProfoundBio CEO) to Board; he committed $3M in PIPE.
- Stockholder support agreements secured for ~36% of shares; termination fee $3.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/0001193125-24-282407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/d891246d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-282407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer